Trial results

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

NCT07845500 on ClinicalTrials.gov · last registry update 2026-10-15

Recruiting now, toward 660 participants. Due to report 16 February 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Percent change from baseline in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Pfizer

Sponsor type

Industry

Enrollment

660

Started

2026-09-30

Primary completion

2028-02-16 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percent change from baseline in body weight

Conditions studied

Obesity · Overweight and/or Obesity · Overweight · Treatment Of Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.